|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:age
|
adults
pediatric patients (≥28 days and weighing at least 3 kg)
|
|
gptkbp:approvalYear
|
2020-10-22
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
J05AB16
|
|
gptkbp:CASNumber
|
1809249-37-3
|
|
gptkbp:chemicalFormula
|
C27H35N6O8P
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to remdesivir
|
|
gptkbp:drugClass
|
antiviral
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:remdesivir
|
|
gptkbp:halfLife
|
1 hour (remdesivir), 25 hours (GS-441524 metabolite)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Veklury
|
|
gptkbp:indication
|
gptkb:COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
hydrolysis and phosphorylation
|
|
gptkbp:patent
|
gptkb:Gilead_Sciences
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
elevated liver enzymes
hypersensitivity
|
|
gptkbp:storage
|
store below 30°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:usedIn
|
hospital settings
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
gptkb:Gilead
|
|
gptkbp:bfsLayer
|
5
|